| Line Item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||
| Revenues (including US$92,046, US$11,002 and nil with related parties for the years ended December 31, 2023, 2024 and 2025, respectively) | |||||||||
| YoY growth | +41.8% | ||||||||
| Cost of revenues (including US$82,237, US$9,426 and nil resulting from related parties sales for the years ended December 31, 2023, 2024 and 2025, respectively) | |||||||||
| Gross profit | |||||||||
| % of revenue | 38.3% | ||||||||
| Operating expenses | |||||||||
| Selling and marketing | |||||||||
| General and administrative | |||||||||
| Research and development | |||||||||
| Total operating expenses | |||||||||
| % of revenue | 49.6% | ||||||||
| Operating loss | |||||||||
| % of revenue | -11.3% | ||||||||
| Other income and expenses | |||||||||
| Interest income | |||||||||
| Interest expenses | |||||||||
| Realized gain from investments | — | ||||||||
| Gain from fair value change of long-term investments | |||||||||
| Impairment loss from investments | |||||||||
| Other (expenses)/income, net | |||||||||
| Loss before income tax and loss from equity method investments | |||||||||
| Income taxes benefits/(expenses) | |||||||||
| Loss before income/(loss) from equity method investments | |||||||||
| Income/(loss) from equity method investments | |||||||||
| Net loss | |||||||||
| % of revenue | -15.5% | ||||||||
| Less: Net loss attributable to non-controlling interest | — | ||||||||
| Net loss attributable to Zepp Health Corporation | |||||||||
| % of revenue | -15.5% | ||||||||
| Net loss attributable to ordinary shareholders of Zepp Health Corporation | |||||||||
| Net loss per share attributable to ordinary shareholders of Zepp Health Corporation | |||||||||
| Basic loss per ordinary share | |||||||||
| Diluted loss per ordinary share |